[EN] CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON S DISEASE<br/>[FR] PROMÉDICAMENTS DE CARBAMATE DE CATÉCHOLAMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
申请人:H LUNDBECK AS
公开号:WO2020234277A1
公开(公告)日:2020-11-26
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
[EN] NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE<br/>[FR] NOUVEAUX PROMÉDICAMENTS DE CATÉCHOLAMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
申请人:H LUNDBECK AS
公开号:WO2019101917A1
公开(公告)日:2019-05-31
The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); (i) (ii) wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.
本发明提供了化合物(I)的中间体,用于治疗神经退行性疾病和紊乱。本发明还提供了包括本发明化合物的药物组合物,以及使用本发明化合物治疗神经退行性或神经精神疾病和紊乱的方法,特别是帕金森病。因此,本发明涉及化合物(I d)的公式,其中R1为H,R2从下面的取代基(i)和(ii)中选择一个;或R1从下面的取代基(i)和(ii)中选择一个,R2为H;或R1和R2都由下面的取代基(i)表示;或R1和R2都由下面的取代基(ii)表示;或R1为取代基(i),R2为取代基(ii);或R1为取代基(ii),R2为取代基(i);(i) (ii) 其中*表示连接点;取代基(i)上连接点的碳原子处于S构型;或其药用可接受盐。
CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF
申请人:Bang-Andersen Benny
公开号:US20120196889A1
公开(公告)日:2012-08-02
The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.
[EN] METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE CARBONATES DE N-HYDROXYSUCCINIMIDYLE
申请人:XENOPORT INC
公开号:WO2010017498A1
公开(公告)日:2010-02-11
The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs.
[EN] CATECHOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF PARKINSON' S DISEASE<br/>[FR] DÉRIVÉS DE CATÉCHOLAMINE UTILES POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
申请人:LUNDBECK & CO AS H
公开号:WO2009026934A1
公开(公告)日:2009-03-05
The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceuticalcompositions containing them and to their use in therapy.